AgingResearch.NewsJoin free

Ruxolitinib + deflazacort

Intervention

1 paper1 finding

PubChem 25126798PubChem 189821ChEBI 66919ChEBI 135720

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

  • 1 lab in 1 country
  • Funder: National Institute of Arthritis and Musculoskeletal and Skin Diseases
  • Animals1

Outcomes

1

Bone microarchitecture

upin mice1

1 study

  1. Ruxolitinib + deflazacort improves bone microarchitecture in mice.

    “treatment of dKO-Hom mice with ruxolitinib and deflazacort synergistically improved bone microarchitecture of the spine L5 vertebrate and the proximal tibia trabecular bone”

    AnimalsdKO-Hom micespine L5 and proximal tibia trabecular bone

    Targeting cellular senescence in dystrophin-/-/utrophin-/-double knockout mice improves musculoskeletal health and increases lifespan

    Pharmacological research30 Oct 2025

Latest

Related